Loading…
Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity
The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity....
Saved in:
Published in: | Frontiers in immunology 2021, Vol.12, p.599526 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413 |
---|---|
cites | cdi_FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413 |
container_end_page | |
container_issue | |
container_start_page | 599526 |
container_title | Frontiers in immunology |
container_volume | 12 |
creator | Binder, Christian Sellberg, Felix Cvetkovski, Filip Berg, Stefan Berglund, Erik Berglund, David |
description | The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc γ receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2
monoclonal antibodies in the absence of Fc γ receptor binding inhibited NK cell activation in allogeneic mixed lymphocyte reaction. In contrast, siplizumab increased NK cell activation in both mixed lymphocyte reaction and autologous lymphocyte culture due to FcγRIIIA binding. However, experiments using purified NK cells did not show an inhibitory effect of CD2 blockade on natural cytotoxicity or antibody-dependent cytotoxicity. Lastly, it was shown that siplizumab induces NK cell fratricide. Concluding, siplizumab is a promising biopharmaceutical drug candidate for depletion of T and NK cells with minimal off-target effects. |
doi_str_mv | 10.3389/fimmu.2021.599526 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b681b0ce2a704f868ecdd8ecade323fd</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b681b0ce2a704f868ecdd8ecade323fd</doaj_id><sourcerecordid>2494881356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413</originalsourceid><addsrcrecordid>eNp1Uk1v1DAQjRCIVqU_gAvKkQNZ_B37grTa0rKiwIEVFw6WY092XZJ46yTA9tfj_WjpHurDeDR-783Yfln2GqMJpVK9r33bjhOCCJ5wpTgRz7JTLAQrKCHs-aP8JDvv-xuUFlOUUv4yO6FUMEqROs1-fvfrxt-NranyeedGC33-9XM-g6bJL6MZorfeQb5YxTAuV_m0G3wV3Ka4gDV0DrphBy2-gPNmAJfPNkMYwt_EGjavshe1aXo4P-xn2eLy42L2qbj-djWfTa8LyxUaClEbXjsEWCirOLJcls4yZ0snOBYEi5LXWBInMTKAjKFGMCwYoVCVJcP0LJvvZV0wN3odfWviRgfj9a4Q4lKbOHjbgK6ExBWyQEyJWC2FBOtcCsYBJbR2SavYa_V_YD1WR2qH0q-UgWaCKlYmvHoSv47B_SfdEzHjSnJGROK-e5J74X9Md5OPo2ZUSSIT_MMenrAtOJvePprmuOPRSedXehl-61Ihlq6aBN4eBGK4HaEfdOt7m37PdBDGXhOmmJSY8u1oeA-1MfR9hPqhDUZ66z69c5_euk_v3Zc4bx7P98C49xr9BzKy2d0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2494881356</pqid></control><display><type>article</type><title>Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity</title><source>PubMed Central</source><creator>Binder, Christian ; Sellberg, Felix ; Cvetkovski, Filip ; Berg, Stefan ; Berglund, Erik ; Berglund, David</creator><creatorcontrib>Binder, Christian ; Sellberg, Felix ; Cvetkovski, Filip ; Berg, Stefan ; Berglund, Erik ; Berglund, David</creatorcontrib><description>The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc γ receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2
monoclonal antibodies in the absence of Fc γ receptor binding inhibited NK cell activation in allogeneic mixed lymphocyte reaction. In contrast, siplizumab increased NK cell activation in both mixed lymphocyte reaction and autologous lymphocyte culture due to FcγRIIIA binding. However, experiments using purified NK cells did not show an inhibitory effect of CD2 blockade on natural cytotoxicity or antibody-dependent cytotoxicity. Lastly, it was shown that siplizumab induces NK cell fratricide. Concluding, siplizumab is a promising biopharmaceutical drug candidate for depletion of T and NK cells with minimal off-target effects.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2021.599526</identifier><identifier>PMID: 33643309</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Antibodies, Monoclonal, Humanized - pharmacology ; Antibody-Dependent Cell Cytotoxicity ; antibody-dependent cell-mediated cytotoxicity ; CD2 ; CD2 Antigens - antagonists & inhibitors ; CD2 Antigens - immunology ; Humans ; Immunology ; Jurkat Cells ; Killer Cells, Natural - immunology ; Lymphocyte Activation - drug effects ; Lymphocyte Depletion ; Medicin och hälsovetenskap ; NK alloreactivity ; NK cell ; Receptors, IgG - immunology ; siplizumab ; spontaneous cytotoxicity</subject><ispartof>Frontiers in immunology, 2021, Vol.12, p.599526</ispartof><rights>Copyright © 2021 Binder, Sellberg, Cvetkovski, Berg, Berglund and Berglund.</rights><rights>Copyright © 2021 Binder, Sellberg, Cvetkovski, Berg, Berglund and Berglund 2021 Binder, Sellberg, Cvetkovski, Berg, Berglund and Berglund</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413</citedby><cites>FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904868/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904868/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4023,27922,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33643309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-439828$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:145985426$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Binder, Christian</creatorcontrib><creatorcontrib>Sellberg, Felix</creatorcontrib><creatorcontrib>Cvetkovski, Filip</creatorcontrib><creatorcontrib>Berg, Stefan</creatorcontrib><creatorcontrib>Berglund, Erik</creatorcontrib><creatorcontrib>Berglund, David</creatorcontrib><title>Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc γ receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2
monoclonal antibodies in the absence of Fc γ receptor binding inhibited NK cell activation in allogeneic mixed lymphocyte reaction. In contrast, siplizumab increased NK cell activation in both mixed lymphocyte reaction and autologous lymphocyte culture due to FcγRIIIA binding. However, experiments using purified NK cells did not show an inhibitory effect of CD2 blockade on natural cytotoxicity or antibody-dependent cytotoxicity. Lastly, it was shown that siplizumab induces NK cell fratricide. Concluding, siplizumab is a promising biopharmaceutical drug candidate for depletion of T and NK cells with minimal off-target effects.</description><subject>Antibodies, Monoclonal, Humanized - pharmacology</subject><subject>Antibody-Dependent Cell Cytotoxicity</subject><subject>antibody-dependent cell-mediated cytotoxicity</subject><subject>CD2</subject><subject>CD2 Antigens - antagonists & inhibitors</subject><subject>CD2 Antigens - immunology</subject><subject>Humans</subject><subject>Immunology</subject><subject>Jurkat Cells</subject><subject>Killer Cells, Natural - immunology</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Lymphocyte Depletion</subject><subject>Medicin och hälsovetenskap</subject><subject>NK alloreactivity</subject><subject>NK cell</subject><subject>Receptors, IgG - immunology</subject><subject>siplizumab</subject><subject>spontaneous cytotoxicity</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1Uk1v1DAQjRCIVqU_gAvKkQNZ_B37grTa0rKiwIEVFw6WY092XZJ46yTA9tfj_WjpHurDeDR-783Yfln2GqMJpVK9r33bjhOCCJ5wpTgRz7JTLAQrKCHs-aP8JDvv-xuUFlOUUv4yO6FUMEqROs1-fvfrxt-NranyeedGC33-9XM-g6bJL6MZorfeQb5YxTAuV_m0G3wV3Ka4gDV0DrphBy2-gPNmAJfPNkMYwt_EGjavshe1aXo4P-xn2eLy42L2qbj-djWfTa8LyxUaClEbXjsEWCirOLJcls4yZ0snOBYEi5LXWBInMTKAjKFGMCwYoVCVJcP0LJvvZV0wN3odfWviRgfj9a4Q4lKbOHjbgK6ExBWyQEyJWC2FBOtcCsYBJbR2SavYa_V_YD1WR2qH0q-UgWaCKlYmvHoSv47B_SfdEzHjSnJGROK-e5J74X9Md5OPo2ZUSSIT_MMenrAtOJvePprmuOPRSedXehl-61Ihlq6aBN4eBGK4HaEfdOt7m37PdBDGXhOmmJSY8u1oeA-1MfR9hPqhDUZ66z69c5_euk_v3Zc4bx7P98C49xr9BzKy2d0</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Binder, Christian</creator><creator>Sellberg, Felix</creator><creator>Cvetkovski, Filip</creator><creator>Berg, Stefan</creator><creator>Berglund, Erik</creator><creator>Berglund, David</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><scope>DOA</scope></search><sort><creationdate>2021</creationdate><title>Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity</title><author>Binder, Christian ; Sellberg, Felix ; Cvetkovski, Filip ; Berg, Stefan ; Berglund, Erik ; Berglund, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies, Monoclonal, Humanized - pharmacology</topic><topic>Antibody-Dependent Cell Cytotoxicity</topic><topic>antibody-dependent cell-mediated cytotoxicity</topic><topic>CD2</topic><topic>CD2 Antigens - antagonists & inhibitors</topic><topic>CD2 Antigens - immunology</topic><topic>Humans</topic><topic>Immunology</topic><topic>Jurkat Cells</topic><topic>Killer Cells, Natural - immunology</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Lymphocyte Depletion</topic><topic>Medicin och hälsovetenskap</topic><topic>NK alloreactivity</topic><topic>NK cell</topic><topic>Receptors, IgG - immunology</topic><topic>siplizumab</topic><topic>spontaneous cytotoxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Binder, Christian</creatorcontrib><creatorcontrib>Sellberg, Felix</creatorcontrib><creatorcontrib>Cvetkovski, Filip</creatorcontrib><creatorcontrib>Berg, Stefan</creatorcontrib><creatorcontrib>Berglund, Erik</creatorcontrib><creatorcontrib>Berglund, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Binder, Christian</au><au>Sellberg, Felix</au><au>Cvetkovski, Filip</au><au>Berg, Stefan</au><au>Berglund, Erik</au><au>Berglund, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2021</date><risdate>2021</risdate><volume>12</volume><spage>599526</spage><pages>599526-</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc γ receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2
monoclonal antibodies in the absence of Fc γ receptor binding inhibited NK cell activation in allogeneic mixed lymphocyte reaction. In contrast, siplizumab increased NK cell activation in both mixed lymphocyte reaction and autologous lymphocyte culture due to FcγRIIIA binding. However, experiments using purified NK cells did not show an inhibitory effect of CD2 blockade on natural cytotoxicity or antibody-dependent cytotoxicity. Lastly, it was shown that siplizumab induces NK cell fratricide. Concluding, siplizumab is a promising biopharmaceutical drug candidate for depletion of T and NK cells with minimal off-target effects.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>33643309</pmid><doi>10.3389/fimmu.2021.599526</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1664-3224 |
ispartof | Frontiers in immunology, 2021, Vol.12, p.599526 |
issn | 1664-3224 1664-3224 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_b681b0ce2a704f868ecdd8ecade323fd |
source | PubMed Central |
subjects | Antibodies, Monoclonal, Humanized - pharmacology Antibody-Dependent Cell Cytotoxicity antibody-dependent cell-mediated cytotoxicity CD2 CD2 Antigens - antagonists & inhibitors CD2 Antigens - immunology Humans Immunology Jurkat Cells Killer Cells, Natural - immunology Lymphocyte Activation - drug effects Lymphocyte Depletion Medicin och hälsovetenskap NK alloreactivity NK cell Receptors, IgG - immunology siplizumab spontaneous cytotoxicity |
title | Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A36%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Siplizumab%20Induces%20NK%20Cell%20Fratricide%20Through%20Antibody-Dependent%20Cell-Mediated%20Cytotoxicity&rft.jtitle=Frontiers%20in%20immunology&rft.au=Binder,%20Christian&rft.date=2021&rft.volume=12&rft.spage=599526&rft.pages=599526-&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2021.599526&rft_dat=%3Cproquest_doaj_%3E2494881356%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2494881356&rft_id=info:pmid/33643309&rfr_iscdi=true |